Corporate
News release
TopANN ARBOR, MICH. -- February 19, 2019 -- Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, and Hemostasis, LLC., today announced a three-year exclusive distribution agreement that will bring BoneSeal® bone hemostat to the United States cardiac surgery market. BoneSeal hemostat is used as a mechanical barrier to control bleeding from cut or damaged bone surfaces. It is comprised of a blend of resorbable, synthetic polymers and biocompatible minerals that promotes bone growth.1
BoneSeal hemostat is a new generation of bone hemostat that effectively stops bleeding upon
application during sternotomy procedures and promotes bone growth during post-operative healing.1
Cardiac surgeons have long-attempted to use various hemostats to manage bleeding from sternotomies, including beeswax, putties, powders and gelatin. BoneSeal hemostat offers a new, all-in-one solution to manage bone hemostasis that is easy to apply and bioabsorbable.
"Terumo CV Group is excited to partner with Hemostasis to bring this innovative product to cardiac surgeons," said Robert DeRyke, Terumo Cardiovascular Group's President and CEO. "Our new agreement to distribute BoneSeal hemostat is yet another way we can positively impact patient care."
BoneSeal hemostat handles much like beeswax and works immediately to achieve bone hemostasis upon application. With BoneSeal hemostat, surgeons can take control of hemostasis and post-operative bleeding, giving patients a better start to healing.1
- 1.
Tham T, Roberts K, Shanahan J, Burban J, Constantino P. Analysis of bone healing with a novel bone wax substitute compared with bone wax in a porcine bone defect model. Future Science OA. 2018 Sep; 4(8): FSO326.
About Terumo Cardiovascular Group
Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit www.terumo-cvgroup.com.
About Hemostasis
Hemostasis designs and manufactures advanced biomaterial-based technologies to facilitate hemostasis and wound healing. Hemostasis products are used in procedures to treat disorders and stop bleeding in sinus, cardiac, orthopedic, vascular, soft tissue and solid organs. Hemostasis is headquartered in Saint Paul, Minnesota. For more information, visit www.hemostasisllc.com. www.hemostasisllc.com
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.